Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBITDA: 2022-2024

Historic EBITDA for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$61.0 million.

  • Orchestra BioMed Holdings' EBITDA fell 35.90% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 30.68%. This contributed to the annual value of -$61.0 million for FY2024, which is 24.10% down from last year.
  • Orchestra BioMed Holdings' EBITDA amounted to -$61.0 million in FY2024, which was down 24.10% from -$49.1 million recorded in FY2023.
  • Orchestra BioMed Holdings' EBITDA's 5-year high stood at -$33.6 million during FY2022, with a 5-year trough of -$61.0 million in FY2024.
  • Over the past 3 years, Orchestra BioMed Holdings' median EBITDA value was -$49.1 million (recorded in 2023), while the average stood at -$47.9 million.
  • Data for Orchestra BioMed Holdings' EBITDA shows a maximum YoY plummeted of 46.13% (in 2023) over the last 5 years.
  • Over the past 3 years, Orchestra BioMed Holdings' EBITDA (Yearly) stood at -$33.6 million in 2022, then crashed by 46.13% to -$49.1 million in 2023, then declined by 24.10% to -$61.0 million in 2024.